Pegaptanib for Neovascular Age-Related Macular Degeneration
Top Cited Papers
- 30 December 2004
- journal article
- research article
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 351 (27) , 2805-2816
- https://doi.org/10.1056/nejmoa042760
Abstract
Pegaptanib, an anti–vascular endothelial growth factor therapy, was evaluated in the treatment of neovascular age-related macular degeneration.Keywords
This publication has 21 references indexed in Scilit:
- Pathologic features of vascular endothelial growth factor-induced retinopathy in the nonhuman primateAmerican Journal of Ophthalmology, 2002
- Prevention of Experimental Choroidal Neovascularization With Intravitreal Anti–Vascular Endothelial Growth Factor Antibody FragmentArchives of Ophthalmology (1950), 2002
- Vascular Endothelial Growth Factor Is Sufficient to Produce Iris Neovascularization and Neovascular Glaucoma in a Nonhuman PrimateArchives of Ophthalmology (1950), 1996
- Inhibition of Vascular Endothelial Growth Factor Prevents Retinal Ischemia—Associated Iris Neovascularization in a Nonhuman PrimateArchives of Ophthalmology (1950), 1996
- Suppression of retinal neovascularization in vivo by inhibition of vascular endothelial growth factor (VEGF) using soluble VEGF-receptor chimeric proteins.Proceedings of the National Academy of Sciences, 1995
- Vascular Endothelial Growth Factor in Ocular Fluid of Patients with Diabetic Retinopathy and Other Retinal DisordersNew England Journal of Medicine, 1994
- Detection of Vascular Endothelial Growth Factor Messenger RNA and Vascular Endothelial Growth Factor-like Activity in Proliferative Diabetic RetinopathyArchives of Ophthalmology (1950), 1994
- Increased Vascular Endothelial Growth Factor Levels in the Vitreous of Eyes With Proliferative Diabetic RetinopathyAmerican Journal of Ophthalmology, 1994
- Vascular Endothelial Growth Factor Is a Secreted Angiogenic MitogenScience, 1989
- Transplacental Carcinogenesis by StilbestrolNew England Journal of Medicine, 1971